Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair

Xu,Jin; Zhu,Wenwei; Xu,Wenyan; Cui,Xiaobo; Chen,Leon; Ji,Shunrong; Qin,Yi; Yao,Wantong; Liu,Liang; Liu,Chen; Long,Jiang; Li,Min; Yu,Xianjun

doi:10.3892/ijo.2013.1901

Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair

Authors:
- Jin Xu
- Wenwei Zhu
- Wenyan Xu
- Xiaobo Cui
- Leon Chen
- Shunrong Ji
- Yi Qin
- Wantong Yao
- Liang Liu
- Chen Liu
- Jiang Long
- Min Li
- Xianjun Yu
View Affiliations

Affiliations: Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China, The Vivian L. Smith Department of Neurosurgery, The University of Texas Medical School at Houston, Houston, TX 77030, USA
Published online on: April 16, 2013 https://doi.org/10.3892/ijo.2013.1901
Pages: 2046-2052

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High resistance to traditional chemo- and radiotherapies contributes to the poor prognosis of pancreatic cancer (PC). Methyl-CpG binding domain protein 1 (MBD1), which plays an important role in disease progression, contributes to the drug resistance of PC cells; however, the mechanism underlying the drug resistance endowed by MBD1 remains unknown. In this study, we found that MBD1 was recruited to DNA damage sites under DNA damage conditions. Silencing of MBD1 significantly impaired activation of the DNA damage checkpoint response and inhibited DNA repair capacity. MBD1 binds mediator of DNA damage checkpoint protein 1 (MDC1), which is induced by radiation and regulates NBS1 activation in the presence of DNA damage repair. Knockdown of MBD1 significantly increased the sensitivity of cells to radiation and cisplatin (diamindichloridoplatin, DDP) in vitro. Importantly, the function of MBD1 in regulating chemoradioresistance is also partially dependent on DNA damage repair. Thus, we hypothesize that MBD1 may promote PC chemoradioresistance by regulating PC cell fate in the presence of DNA damage. Collectively, these findings reveal an important function of MBD1 in DNA repair and mediation of chemoradioresistance of cancer cells. Moreover, this study suggests that MBD1 is a promising molecular target for sensitizing resistant PC tumor cells to chemoradiotherapy.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Erkan M, Hausmann S, Michalski CW, et al: The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 9:454–467. 2012. View Article : Google Scholar : PubMed/NCBI
3	Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 6:412–422. 2009. View Article : Google Scholar : PubMed/NCBI
4	Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
5	Garrido-Laguna I, Uson M, Rajeshkumar NV, et al: Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 17:5793–5800. 2011. View Article : Google Scholar : PubMed/NCBI
6	Terry SY and Vallis KA: Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy. Int J Radiat Oncol Biol Phys. 83:1298–1305. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ng HH, Jeppesen P and Bird A: Active repression of methylated genes by the chromosomal protein MBD1. Mol Cell Biol. 20:1394–1406. 2000. View Article : Google Scholar : PubMed/NCBI
8	Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F and Esteller M: A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res. 66:8342–8346. 2006. View Article : Google Scholar : PubMed/NCBI
9	Liu C, Chen Y, Yu X, et al: Proteomic analysis of differential proteins in pancreatic carcinomas: effects of MBD1 knockdown by stable RNA interference. BMC Cancer. 8:1212008. View Article : Google Scholar : PubMed/NCBI
10	Watanabe S, Ichimura T, Fujita N, et al: Methylated DNA-binding domain 1 and methylpurine-DNA glycosylase link transcriptional repression and DNA repair in chromatin. Proc Natl Acad Sci USA. 100:12859–12864. 2003. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Chen LH, Wang L, Wang HM, Zhang YW and Shi YS: Radiation-inducible PTEN expression radiosensitises hepatocellular carcinoma cells. Int J Radiat Biol. 86:964–974. 2010. View Article : Google Scholar : PubMed/NCBI
12	Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004. View Article : Google Scholar : PubMed/NCBI
13	Bekker-Jensen S, Lukas C, Kitagawa R, et al: Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol. 173:195–206. 2006. View Article : Google Scholar : PubMed/NCBI
14	Jirawatnotai S, Hu Y, Michowski W, et al: A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 474:230–234. 2011. View Article : Google Scholar : PubMed/NCBI
15	Löbrich M, Shibata A, Beucher A, et al: gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle. 9:662–669. 2010.PubMed/NCBI
16	Bartkova J, Horejsí Z, Koed K, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 434:864–870. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
18	Chapman JR and Jackson SP: Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage. EMBO Rep. 9:795–801. 2008. View Article : Google Scholar : PubMed/NCBI
19	Harper JW and Elledge SJ: The DNA damage response: ten years after. Mol Cell. 28:739–745. 2007.PubMed/NCBI
20	Zhou BB and Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature. 408:433–439. 2000. View Article : Google Scholar : PubMed/NCBI
21	Yao W, Yu X, Fang Z, et al: Profilin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin betal-actin complex in breast cancer cells. J Cell Mol Med. 16:824–835. 2012. View Article : Google Scholar : PubMed/NCBI
22	Shibamoto Y, Kubota T, Kishii K and Tsujitani M: Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol. 56:265–270. 2000. View Article : Google Scholar : PubMed/NCBI
23	Kim MP and Gallick GE: Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res. 14:1284–1285. 2008. View Article : Google Scholar : PubMed/NCBI
24	Parsels LA, Morgan MA, Tanska DM, et al: Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther. 8:45–54. 2009. View Article : Google Scholar : PubMed/NCBI
25	Krempler A, Deckbar D, Jeggo PA and Lobrich M: An imperfect G2M checkpoint contributes to chromosome instability following irradiation of S and G2 phase cells. Cell Cycle. 6:1682–1686. 2007. View Article : Google Scholar : PubMed/NCBI
26	Bartek J and Lukas J: Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol. 13:738–747. 2001. View Article : Google Scholar : PubMed/NCBI
27	Taverna SD, Li H, Ruthenburg AJ, Allis CD and Patel DJ: How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 14:1025–1040. 2007. View Article : Google Scholar : PubMed/NCBI
28	Mailand N, Falck J, Lukas C, et al: Rapid destruction of human Cdc25A in response to DNA damage. Science. 288:1425–1429. 2000. View Article : Google Scholar : PubMed/NCBI
29	Helt CE, Cliby WA, Keng PC, Bambara RA and O’Reilly MA: Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem. 280:1186–1192. 2005. View Article : Google Scholar : PubMed/NCBI
30	Falck J, Mailand N, Syljuasen RG, Bartek J and Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 410:842–847. 2001. View Article : Google Scholar : PubMed/NCBI
31	Kouzarides T: Snapshot: histone-modifying enzymes. Cell. 131:8222007. View Article : Google Scholar : PubMed/NCBI
32	Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ and Jackson SP: MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell. 123:1213–1226. 2005. View Article : Google Scholar : PubMed/NCBI
33	Wu L, Luo K, Lou Z and Chen J: MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks. Proc Natl Acad Sci USA. 105:11200–11205. 2008. View Article : Google Scholar : PubMed/NCBI